News | February 03, 2025
Jubilant Pharmova Q3 FY25 revenue up 9%
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Investment will fund expansion to meet rising demand for CRDMO services
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Executes the first project for developing and manufacturing a novel anticancer mAb
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Subscribe To Our Newsletter & Stay Updated
